专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2625293A4 MICRORNAS (MIRNA) AS BIOMAKERS FOR THE IDENTIFICATION OF FAMILIAL AND NON-FAMILIAL COLORECTAL CANCER 审中-公开
标题翻译：微小RNA（自然资源部）作为生物标志物用于识别家庭与条件不熟悉有条件结直肠癌
公开(公告)号：EP2625293A4
公开(公告)日：2014-03-19
申请号：EP11831689
申请日：2011-10-07
申请人： BAYLOR RES INST , HOSPITAL CLINIC BARCELONA , CT DE INVESTIGACION EN RED DE ENFERMEDADES HEPATICAS Y DIGESTIVAS
发明人： GOEL AJAY , BOLAND RICHARD C , BALAGUER FRANCESC , GIRONELLA I COS MERITXELL , CASTELLS I GARANGOU ANTONI , MOREIRA RUIZ LETICIA , LOZANO SALVATELLA JUAN JOSE
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , C12Q2600/178

2. 发明专利

CA2814081A1 MICRORNAS (MIRNA) AS BIOMAKERS FOR THE IDENTIFICATION OF FAMILIAL AND NON-FAMILIAL COLORECTAL CANCER 未知
公开(公告)号：CA2814081A1
公开(公告)日：2012-04-12
申请号：CA2814081
申请日：2011-10-07
申请人： BAYLOR RES INST , HOSPITAL CLINIC BARCELONA , CT DE INVESTIGACION EN RED DE ENFERMEDADES HEPATICAS Y DIGESTIVAS
发明人： GOEL AJAY , BOLAND RICHARD C , BALAGUER FRANCESC , GIRONELLA I COS MERITXELL , CASTELLS I GARANGOU ANTONI , MOREIRA RUIZ LETICIA , LOZANO SALVATELLA JUAN JOSE
IPC分类号： C12Q1/68
摘要： A technique for the analysis of global miRNA signatures including a larger panel of miRNAs in various roups of well-characterized colorectal cancers (CRCs) is described in the instant invention. The results presented herein provide a large list of miRNAs that are dysregulated in CRC compared to the normal colonic tissue, and, more importantly, the present invention shows for the first time that Lynch syndrome and sporadic MSI tumors exhibit a different miRNA signature that distinguishes them.

3. 发明专利

AU2011311881A1 MicroRNAs (miRNA) as biomakers for the identification of familial and non-familial colorectal cancer 未知
公开(公告)号：AU2011311881A1
公开(公告)日：2013-05-02
申请号：AU2011311881
申请日：2011-10-07
申请人： BAYLOR RES INSTITUTE , CENTRO DE INVESTIG EN RED DE ENFERMEDADES HEPATICAS Y DIGESTIVAS , HOSPITAL CLINIC BARCELONA
发明人： GOEL AJAY , BOLAND RICHARD C , BALAGUER FRANCESC , GIRONELLA I COS MERITXELL , CASTELLS I GARANGOU ANTONI , MOREIRA RUIZ LETICIA , LOZANO SALVATELLA JUAN JOSE
IPC分类号： C12Q1/68
摘要： A technique for the analysis of global miRNA signatures including a larger panel of miRNAs in various roups of well-characterized colorectal cancers (CRCs) is described in the instant invention. The results presented herein provide a large list of miRNAs that are dysregulated in CRC compared to the normal colonic tissue, and, more importantly, the present invention shows for the first time that Lynch syndrome and sporadic MSI tumors exhibit a different miRNA signature that distinguishes them.

4. 发明公开

EP2794924A4 IDENTIFICATION OF METASTASIS-SPECIFIC MIRNA AND HYPOMETHYLATION SIGNATURES IN HUMAN COLORECTAL CANCER 失效转让
标题翻译： IDENTIFIZIERUNG VON METASTASENSPEZIFISCHER MIRNA UND HYPOMETHYLIERUNGSSIGNATUREN BEI MENSCHLICHEM KOLOREKTALKARZINOM
公开(公告)号：EP2794924A4
公开(公告)日：2015-12-23
申请号：EP12859326
申请日：2012-12-21
申请人： BAYLOR RES INST
发明人： GOEL AJAY , BOLAND RICHARD C , HUR KEUN
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2525/207 , C12Q2600/154 , C12Q2600/178
摘要： The present invention includes methods and biomarkers for diagnosing or detecting colorectal cancer metastasis in a human subject by comparing the Alu repeat methylation level in the biological sample to an Alu repeat methylation control level from a normal non-cancerous sample from the human subject, wherein a decrease in the Alu repeat methylation level is indicative of colorectal cancer and colorectal cancer metastasis. The invention also includes methods and biomarkers for diagnosing or detecting colorectal cancer (CRC) metastasis in a human subject by determining a level of expression of let-7i, miR-10b, miR-320a, and miR-221 in the sample from the one or more biological samples; and comparing the level of expression of let-7i, miR-10b, miR-320a, and miR-221 in the sample with the level of expression of let-7i, miR-10b, miR-320a, and miR-221 from normal colorectal tissue, wherein high expression of at least on of let-7i or miR-320a is indicative of a good prognosis for the CRC, while the low expression of at least one of miR-10b or miR-221 is indicative of a good prognosis for the CRC or CRC metastasis.
摘要翻译：本发明包括通过将生物样品中的Alu重复甲基化水平与来自人类受试者的正常非癌性样品的Alu重复甲基化对照水平进行比较来诊断或检测人类受试者的结肠直肠癌转移的方法和生物标志物，其中a Alu重复甲基化水平的降低指示结肠直肠癌和结肠直肠癌转移。本发明还包括用于通过测定样品中let-7i，miR-10b，miR-320a和miR-221的表达水平来诊断或检测人受试者中的结肠直肠癌（CRC）转移的方法和生物标志物或更多的生物样品; 并将样品中let-7i，miR-10b，miR-320a和miR-221的表达水平与let-7i，miR-10b，miR-320a和miR-221的表达水平与正常结肠直肠组织，其中至少对let-7i或miR-320a的高表达指示CRC的良好预后，而miR-10b或miR-221中的至少一种的低表达指示良好的预后用于CRC或CRC转移。

5. 发明公开

EP2971132A4 TISSUE AND BLOOD-BASED MIRNA BIOMARKERS FOR THE DIAGNOSIS, PROGNOSIS AND METASTASIS-PREDICTIVE POTENTIAL IN COLORECTAL CANCER 有权转让
标题翻译：用于诊断，预测和预测彩色直肠癌转移灶潜能的织物和基于血液的MIRNA生物标记物
公开(公告)号：EP2971132A4
公开(公告)日：2016-10-19
申请号：EP14764952
申请日：2014-03-17
申请人： BAYLOR RES INST
发明人： GOEL AJAY , HUR KEUN , TOIYAMA YUJI , BOLAND RICHARD C
IPC分类号： C12Q1/68 , C12P19/34 , C40B40/06
CPC分类号： C12Q1/6886 , A61B1/31 , C12Q2600/178
摘要： Methods and compositions for the diagnosis, prognosis and classification of cancer, especially colorectal cancer, are provided. For example, in certain aspects methods for cancer prognosis using expression or methylation analysis of selected biomarkers are described. Particular aspects of the present invention may include methods and biomarkers for diagnosing or detecting colorectal cancer or metastasis in a subject by measuring a level of expression of biomarker miRNA such as miR-885-5p in the sample from the subject and evaluating the risk of developing cancer or metastasis in the subject.

6. 发明专利

AR078584A1 IDENTIFICACION DE MICROARN (MIARN) EN MUESTRAS FECALES COMO BIOMARCADOR DE CANCERES GASTROENTEROLOGICOS 未知
公开(公告)号：AR078584A1
公开(公告)日：2011-11-16
申请号：ARP100103699
申请日：2010-10-08
申请人： BAYLOR RES INST
发明人： GOEL AJAY , BOLAND RICHARD C , LINK ALEXANDER , BALAGUER FRANCESC
IPC分类号： C12Q1/68 , G01N33/52 , G01N33/574
摘要： Un método de ensayo comercial con biomarcadores para el diagnostico de multiples enfermedades que es simple, rápido, economico y prometedor. Por medio de la presente, pueden detectarse biomarcadores basados en miARN en especímenes de heces humanas. El método de la presente permite amplificar el miARN directamente a partir de los especímenes de heces, sin que sea necesario extraer el miARN con antelacion. La expresion diferencial de un microARN específico en las heces de pacientes que padecen un cáncer colorrectal o un adenoma es indicativa de la posibilidad de usar el microARN fecal como un biomarcador potencial para la deteccion de las neoplasias colorrectales. El método de la presente tiene relevancia para el diagnostico, el pronostico y la terapia de los cánceres gastroenterologicos/colorrectales y de las enfermedades gastrointestinales adquiridas o hereditarias. Reivindicacion 1: Un método para aislar y amplificar uno o más microARN (miARN) a partir de una muestra biologica, que comprende los siguientes pasos: mezclar una muestra fecal con una solucion de una sal, agua libre de ARNasa o ambas para formar una suspension; centrifugar la suspension; separar el sobrenadante de la suspension centrifugada; medir la concentracion de ARN/miARN total en el sobrenadante usando un espectrofotometro; transcribir ADNc a partir del ARN total usando uno o más cebadores específicos para el miARN; y amplificar el ADNc transcripto usando un ensayo de reaccion en cadena de la polimerasa (PCR), con el fin de obtener uno o más miARN amplificados.

7. 发明专利

CA2859865A1 IDENTIFICATION OF METASTASIS-SPECIFIC MIRNA AND HYPOMETHYLATION SIGNATURES IN HUMAN COLORECTAL CANCER 未知
公开(公告)号：CA2859865A1
公开(公告)日：2013-06-27
申请号：CA2859865
申请日：2012-12-21
申请人： BAYLOR RES INST
发明人： GOEL AJAY , BOLAND RICHARD C , HUR KEUN
IPC分类号： C12Q1/68
摘要： The present invention includes methods and biomarkers for diagnosing or detecting colorectal cancer metastasis in a human subject by comparing the Alu repeat methylation level in the biological sample to an Alu repeat methylation control level from a normal non-cancerous sample from the human subject, wherein a decrease in the Alu repeat methylation level is indicative of colorectal cancer and colorectal cancer metastasis. The invention also includes methods and biomarkers for diagnosing or detecting colorectal cancer (CRC) metastasis in a human subject by determining a level of expression of let-7i, miR-10b, miR-320a, and miR-221 in the sample from the one or more biological samples; and comparing the level of expression of let-7i, miR-10b, miR-320a, and miR-221 in the sample with the level of expression of let-7i, miR-10b, miR-320a, and miR-221 from normal colorectal tissue, wherein high expression of at least on of let-7i or miR-320a is indicative of a good prognosis for the CRC, while the low expression of at least one of miR-10b or miR-221 is indicative of a good prognosis for the CRC or CRC metastasis.

8. 发明专利

AU2012358200A1 Identification of metastasis-specific miRNA and hypomethylation signatures in human colorectal cancer 未知
公开(公告)号：AU2012358200A1
公开(公告)日：2014-08-07
申请号：AU2012358200
申请日：2012-12-21
申请人： BAYLOR RES INST
发明人： GOEL AJAY , BOLAND RICHARD C , HUR KEUN
IPC分类号： C12Q1/68
摘要： The present invention includes methods and biomarkers for diagnosing or detecting colorectal cancer metastasis in a human subject by comparing the Alu repeat methylation level in the biological sample to an Alu repeat methylation control level from a normal non-cancerous sample from the human subject, wherein a decrease in the Alu repeat methylation level is indicative of colorectal cancer and colorectal cancer metastasis. The invention also includes methods and biomarkers for diagnosing or detecting colorectal cancer (CRC) metastasis in a human subject by determining a level of expression of let-7i, miR-10b, miR-320a, and miR-221 in the sample from the one or more biological samples; and comparing the level of expression of let-7i, miR-10b, miR-320a, and miR-221 in the sample with the level of expression of let-7i, miR-10b, miR-320a, and miR-221 from normal colorectal tissue, wherein high expression of at least on of let-7i or miR-320a is indicative of a good prognosis for the CRC, while the low expression of at least one of miR-10b or miR-221 is indicative of a good prognosis for the CRC or CRC metastasis.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式